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Background:  The  clinical  characteristics  and  prognostic  factors  of  thymic  carcinoma  have  not  been investi-
gated in detail  because  of its  rarity.  The  aim  of this  study  was  to elucidate  the  disease  proﬁle,  outcomes,  and
prognostic  factors  for  survival  among  patients  with  advanced  thymic  carcinoma  treated  with  palliative-
intent  chemotherapy.
Patients  and  methods:  A retrospective  review  was  conducted  of  the  medical  records  of 40  patients  treated
with palliative-intent  chemotherapy  for advanced  thymic  carcinoma  between  1991 and  2011 in our
institution.  Clinical  demographics,  histology,  overall  survival,  and  factors  expected  to  predict  survival
were analyzed.  Differences  in  survival  were  assessed  using  Kaplan–Meier  analysis  and  univariate  and
multivariate  Cox  proportional  hazards  regression  analyses.
Results:  The  study  included  22 males  (55.0%)  and 18  females  (45.0%).  The  median  age  at  diagnosis  was
58.5  years.  The  most  common  metastatic  sites  at diagnosis  were  lung  (45.0%),  lymph  nodes  (20.0%),
liver  (15.0%),  bone  (15.0%),  and  brain  (5.0%).  The  most  common  histological  subtypes  were  squamous
cell  carcinoma  (70.0%),  followed  by  neuroendocrine  carcinoma  (17.5%),  and  mucoepidermoid  carcinoma
(7.5%). The  response  rate  for ﬁrst-line  chemotherapy  was  47.5%.  The  median  survival  time  was  24.5
months  (95%  conﬁdence  interval  20.9-43.5  months).  Overall  survival  rates  at  1-, 2-, and  5-years  were
72.5%,  52.5%,  and  17.5%,  respectively.  In uni- and  multivariate  analyses,  the only  favorable  prognostic
factor  for  overall  survival  was response  to  ﬁrst-line  chemotherapy  (p = 0.01).
Conclusion:  Response  to  ﬁrst-line  chemotherapy  may  be  implicated  as  a  potential  surrogate  for  survival
in advanced  thymic  carcinoma.. Introduction
Thymic epithelial neoplasm (TEN) is a rare cancer comprising
hymoma, thymic carcinoma, and thymic neuroendocrine carci-
oma; it has an annual incidence of 0.15 per 100,000 person-years
1].  The European Union deﬁnes a rare cancer as any cancer with
n incidence of less than 6 per 100,000 persons per year; thus,
ased on these criteria, TEN is considered a rare disease and thymic
arcinoma accounts for less than 1-4% of cases of TEN. Thymic
arcinoma is deﬁnitively distinguished from thymoma based on
iological characteristics and clinical prognosis. However, it is
ifﬁcult to fully understand the clinical characteristics and pro-
nostic factors among patients with advanced thymic carcinoma
ecause of its rarity. Thymic carcinoma does not preserve the cor-
ex or medulla of the thymus, therefore, causing the loss of thymic
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function. In contrast, thymoma induces the development of
CD4+/CD8+ double positive T-cells. Thus, paraneoplastic syn-
dromes induced by autoantibodies, such as myasthenia gravis, pure
red cell aplasia, or hypogammaglobulinemia, do not occur in thymic
carcinoma [2,3]. No overt symptoms appear during the early stage;
rather, the initial symptoms tend to occur with tumor extension or
metastasis. Therefore, thymic carcinoma is usually diagnosed after
extension with poor prognosis. Patients in the advanced stages of
thymic carcinoma (Masaoka–Koga stage IVa, IVb, or recurrent dis-
ease) are usually treated with palliative-intent chemotherapy or
best supportive care. Patients with stage IVa disease have been
shown to experience prolonged survival with multimodality treat-
ment in combination with curative-intent surgery, radiotherapy,
and chemotherapy [4]. Wekslter et al. demonstrated the survival
beneﬁt with surgical intervention [5].  There is only a low level
Open access under CC BY-NC-ND license.of evidence in support of chemotherapy, with a few retrospec-
tive studies based on small groups of treated patients with diverse
backgrounds are available; thus, the optimal therapeutic strat-
egy remains controversial. The rarity of this orphan tumor has
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recluded it from undergoing prospective studies. When limited
o thymic carcinoma, Lemma  et al. showed a moderate response to
arboplatin and paclitaxel in a phase II trial [6].  Other prospective
linical trials have provided evidence on the efﬁcacy of chemother-
py for only thymoma. Overall, the prognosis and prognostic factors
ave not been well investigated in advanced thymic carcinoma.
The objective of the present study was to retrospectively
valuate the clinical characteristics, prognosis, and prognostic fac-
ors of thymic carcinoma among patients with advanced thymic
arcinoma treated with palliative-intent chemotherapy in our insti-
ution.
. Patients and methods
.1. Database
Patients treated with palliative-intent chemotherapy for
dvanced thymic carcinoma were identiﬁed from the databases
t Tokyo Metropolitan Cancer and Infectious diseases Center
omagome Hospital (Tokyo, Japan) between January 1, 1991 and
ecember 31, 2011. Codes were used from the International Clas-
iﬁcation of Diseases (9th edition). This study was approved by the
nstitutional review board.
.2. Data acquisition
A retrospective review was performed to collect data on the
utcomes of 40 consecutive patients treated with chemotherapy
or thymic carcinoma of Masaoka–Koga stage IVa, IVb, or recurrent
isease. Thymic carcinoma was conﬁrmed by hematoxylin–eosin
taining and immunohistochemistry using CD5 and/or CD117 (c-
IT) to exclude other malignant thoracic tumors, and/or terminal
eoxynucleotidyl transferase (TdT) to distinguish from thymoma
t initial diagnosis. The pathological review was performed con-
istently by a specialist in thymic malignancies. Individuals with
 histological diagnosis of thymoma were excluded. Recurrent
isease was deﬁned as disease that was not responsive to
urative-intent treatment; all patients with recurrent disease
ere chemonaïve and underwent palliative-intent chemotherapy.
ecurrent disease was determined by chest computed tomography,
agnetic resonance imaging, positron emission tomography, or
one scanning. Histology was also classiﬁed according to the WHO
lassiﬁcation, and staging was determined by the Masaoka–Koga
taging system. We  also examined such clinical factors as age,
taging, Eastern Cooperative Oncology Group Performance Sta-
us, cigarette smoking, initial symptoms at diagnosis, metastasis
o distant organs, histology, treatment modality, response to ﬁrst-
ine chemotherapy as deﬁned by radiographic images, number
f later lines of chemotherapy, and survival. In terms of his-
ology, we analyzed survival according to low-grade histology
squamous cell carcinoma, mucoepidermoid carcinoma, and basa-
oid carcinoma) and high-grade histology (lymphoepithelioma-like
arcinoma, neuroendocrine carcinoma, clear cell carcinoma, sarco-
atoid carcinoma, and undifferentiated carcinoma) as deﬁned by
uster and Rosai [7].  Data were collected in accordance with the
nternational Thymic Malignancy Interest Group (ITMIG) Standard
eﬁnitions and Policies [4].  The medical records and laboratory
ata for each patient were retrieved for analysis and assessment
f treatments for thymic carcinoma. In patients with stage IVa dis-
ase, survival time was deﬁned as the length of time from the day
hen the patient began ﬁrst-line palliative-intent chemotherapyexcluding the adjuvant setting if the patient underwent surgery)
o the day of death. Patients were treated with palliative-intent
hemotherapy, with or without a combination of radiotherapy in
he ﬁrst-line setting. A “responder” was deﬁned as a patient whoer 80 (2013) 75– 80
achieved complete response or partial response as assessed by the
Response Evaluation Criteria in Solid Tumors criteria version 1.1
(RECIST 1.1) with ﬁrst-line chemotherapy. A “non-responder” was
deﬁned as a patient with stable disease or progressive disease.
2.3. Statistical analysis
The primary end point was the association between several pro-
gnostic factors and overall survival. Survival time was deﬁned as
the period from the date of initiation of ﬁrst-line chemotherapy
to the date of death from any cause or last follow-up using the
Kaplan–Meier method. Patients lost to follow-up were censored at
the time of last contact. Due to the retrospective nature of the data,
these relevant end points were chosen to reﬂect clinical practice.
The Kaplan–Meier method was  used to estimate overall survival,
1-year, 2-year, and 5-year survival. The log-rank test was  used to
identify prognostic factors for survival in the univariate analysis.
Variables analyzed included age (<65 vs. ≥65 years), gender (male
vs. female), histology (low-grade vs. high-grade), disease stage (IVa
vs. IVb vs. recurrent), serum lactate dehydrogenase (LDH) level at
diagnosis (<200 IU/dL vs. ≥200 IU/dL), and response to ﬁrst-line
chemotherapy (responder vs. non-responder) in uni- and multi-
variate analyses. Signiﬁcant factors (p < 0.05) in univariate analysis
were included in the multivariate Cox proportional hazards model.
All statistical analyses were performed using SAS (SAS Institute Inc.,
Cary, NC, USA).
3. Results
3.1. Patient characteristics
A total of 40 patients (22 males, 18 females) were treated with
palliative-intent chemotherapy for advanced thymic carcinoma.
Their median age was 58.5 years (range, 14–83 years). At ini-
tial diagnosis, thymic carcinoma had metastasized to the lungs,
liver, and bone. At diagnosis, 10 patients (25.0%) had stage IVa
disease, 22 patients (55.0%) had stage IVb disease, and 8 patients
had recurrent disease (20.0%). Histologic examination revealed 6
subtypes of thymic carcinoma: 28 patients had squamous cell
carcinoma (70.0%), 7 patients (17.5%) had neuroendocrine carci-
noma (3 patients had small cell carcinoma, 2 patients had large
cell neuroendocrine carcinoma, and 2 patients had carcinoid), 3
patients had mucoepidermoid carcinoma (7.5%), and 1 patient
had lymphepithelioma-like carcinoma. No patients complicated by
autoimmune-related symptoms were observed. Patient character-
istics are shown in Table 1.
3.2. Outcome of chemotherapy and factors affecting survival
The types of ﬁrst-line chemotherapy administered are also
shown in Table 1. For ﬁrst-line chemotherapy, 11 patients (27.5%)
received ADOC, consisting of cisplatin, adriamycin, vincristine,
and cyclophosphamide; 10 patients (25.0%) received IP, con-
sisting of irinotecan and cisplatin; 12 patients (30.0%) received
other cisplatin-containing regimens; 3 patients (7.5%) received
carboplatin-based doublets chemotherapy; and 4 patients (10.0%)
received single agent or non-platinum-based therapy. Disease
control was observed in 31 patients (77.5%), with 19 showing par-
tial responses (47.5%) and 12 showing stable disease (30.0%); 9
patients (22.5%) had progressive disease. There were no complete
responders. The response rate for patients treated with cisplatin-
containing chemotherapy (n = 33) was 51.5%, and the response
rate for cisplatin and anthracycline-containing chemotherapy
(n = 11) was  36.3%. The response rate for platinum-based doublet
chemotherapy with a third generation agent (n = 14) was 50.0%.
The median survival time for all patients was  24.5 months (95%
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Table 1
Characteristics of 40 patients with advanced thymic carcinoma by chemotherapy.
Characteristics No of patients (n = 40) (%)
Median age, years (range) 58.5 [14–83] – –
Gender Male/female 22/18 55.0/45.0
ECOG-PS 0/1/2 14/26/0 35.0/65.0/0.0
Smoking status Never smoked 18 45.0
Previously smoked/current smoker 22 55.0
Symptom at diagnosis Symptomatic/asymptomatic 29/11 72.5/27.5
Histology Low-grade 31 77.5
Squamous cell carcinoma 28 70.0
Mucoepidermoid carcinoma 3 7.5
High-grade 9 22.5
Lymphoepithelioma-like carcinoma 1 2.5
Undifferentiated carcinoma 1 2.5
Neuroendocrine carcinomas 7 17.5
Poorly differentiated neuroendocrine carcinomas 5 12.5
Small cell carcinoma 3 7.5
Large cell neuroendocrine carcinoma 2 5.0
Well differentiated neuroendocrine carcinomas 2 5.0
Staging (Masaoka–Koga) IVa/IVb/recurrent 10/22/8 25.0/55.0/20.0
Metastatic site PUL/LYM/HEP/OSS/BRA 18/8/6/6/2 45.0/20.0/15.0/15.0/5.0
LDH  (IU/mL) <200/≥ 200 18/22 45.0/55.0
First-line chemotherapy ADOC 11 27.5
CDDP/CPT-11 10 25.0
Other cisplatin-containing chemotherapyc 12 30.0
Carboplatin-containing chemotherapyd 3 7.5
Single-agent or non-platinum combination chemotherapye 4 10.0
Response to chemotherapy CR/PR 0/19 0.0/47.5
SD/PD 12/9 30.0/22.5
Use  of 3rd generation anti-cancer agentsb Yes/no 15/25 37.5/62.5
Later  lines of chemotherapya Yes/no 22/18 55.0/45.0
PUL: lung; OSS: bone; HEP: liver; HEP: liver; LYM: extrathoracic lymph node, BRA: brain; ADOC: cisplatin/adriamycin/vincristine/cyclophosphamide; CDDP: cisplatin; CPT-11:
irinotecan; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
a Median later lines of chemotherapy was  1 line in all patients.
b Amrubicin, Docetaxel, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, S-1, Vinorelbine.
c Including Cisplatin/Gemcitabine, Cisplatin/Paclitaxel, Cisplatin/Bleomycin/Etoposide, 2 patients with Mitomycin/Vindesine/Cisplatin (MVP), 2 patients with Cis-
platin/Etoposide, 2 patients with Cyclophosphamide/Doxorubicin/Vincristine and Cisplatin/Etoposide (CAP/PVP) alternating chemotherapy, and 3 patients with
Cisplatin/Vindesine.
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cIncluding Carboplatin/Gemcitabine, Carboplatin/Paclitaxel, and Carboplatin/Mi
e Including S-1, Cisplatin, Mitomycine/Cyclophosphamide/5-ﬂuorouracil and Cyc
I, 20.9-43.5 months). The survival curve is shown in Fig. 1-A: 1-
ear, 2-year, and 5-year survival rates were 72.5%, 52.5%, and 17.5%,
espectively. A median later line of chemotherapy was one-line.
hese results were associated with reported studies in patients
reated with palliative-intent chemotherapy for advanced thymic
arcinoma.
A subgroup analysis was performed among the patients with
aving a numerically superior response to ﬁrst-line chemotherapy
s. the non-responders (43.6 months vs. 24.5 months) in terms of
edian survival time (p = 0.02, Fig. 1-B). In terms of staging, patients
ith stage IVa disease had a median survival of 35.4 months com-
ared with 26.0 months for patients with recurrent disease and
0.9 months for patients with stage IVb disease; however, these
ifferences were not signiﬁcant (p = 0.64). Other factors such as age,
ender, histological grade, and serum level of LDH did not have any
igniﬁcant impact on survival (Table 2). In the multivariate analysis,
esponse to ﬁrst-line chemotherapy still demonstrated signiﬁcant
ositive impact on survival among the items of clinical interest
Table 3).
. DiscussionThe present retrospective analysis involved 40 patients treated
ith palliative-intent chemotherapy for advanced thymic car-
inoma. The results indicated that patients who  responded toin/Vindesine.
sphamide/Doxorubicin/Vincristine/Predonisolone (CHOP).
ﬁrst-line chemotherapy might have a better prognosis than refrac-
tory patients.
In 1977, thymic carcinoma, an atypical form of carcinoma, was
reported by Shimosato et al., and was  thereafter deﬁned as type
C thymoma by the WHO  classiﬁcation 1999 [8].  This classiﬁcation
was referred to by Muller-Hermilink et al. [9] and classiﬁed with
neuroendocrine carcinoma, germ cell tumors, and lymphoepithe-
lial subtypes. In the 2004 WHO  classiﬁcation, thymic carcinoma
was distinguished from thymoma [10]. In addition, thymic neu-
roendocrine carcinoma was also moved from the category of
conventional thymic carcinoid to the category of thymic carcinoma.
The histologic grade of thymic carcinoma has been reported
to inﬂuence prognosis [11,12]. Overall, 60–70% of subtypes are
squamous cell carcinoma and lymphoepithelioma-like carcinoma.
Recently, a molecular investigation revealed that c-KIT expression
is more positive in thymic carcinoma (75%) than in thymoma (2%).
Furthermore, overexpression of c-KIT is also a negative progno-
stic factor [13]. Thus, the choice of treatment for thymic carcinoma
appears to depend on the biological background.
Distant metastases are demonstrated in 1.5–15.5% of patients
with thymic carcinoma; pulmonary, hepatic, or bone metastases
are relatively common [14]. Brain metastasis, however, seems to
occur relatively less often. One case study found that brain metas-
tases occurred in 12.2% (6/49) of the advanced stage patients [15].
In our series, brain metastases (5.0%) occurred less frequently than
78 Y. Okuma et al. / Lung Cancer 80 (2013) 75– 80
Table 2
Prognostic signiﬁcance for survival among advanced thymic carcinoma patients treated with chemotherapy in univariate analysis.
Variants Cut-off No of patients MST  [95% conﬁdence interval) p-value
Age <65 23 23.3 [10.0–43.6] 0.39
≥65 17 31.1 [21.5–67.3]
Gender Male 18 23.1 [10.1–31.1] 0.15
Female 22 35.4 [18.6–97.8]
Histology Low-grade 31 26.0 [20.9–43.6] 0.83
High-grade 9 24.5 [5.6–78.6]
Stage IVa  10 35.4 [18.6–not reached] 0.64
IVb 22 20.9 [9.6–45.0]
Rec  8 26.0 [14.5–57.8]
Serum level of LDH LDH < 200 18 31.1 [17.1–67.3] 0.54
LDH  ≥ 200 22 24.1 [10.1–43.5]
Use  of 3rd generation Yes 25 24.3 [8.2–not reached] 0.62
Anti-cancer agents No 15 26.0 [18.6–43.6]
Response for 1st line
chemotherapy
Responder [CR/PR] 19 43.6 [23.3–not reached] 0.02*
Non-responder [SD/PD] 21 21.5 [9.3–33.8]
P rogen
t
n
r
d
F
o
2
[
g
iR: partial response; SD: stable disease; PD: progressive disease; LDH: lactic dehyd
* p < 0.05.
he metastasis seen in other intrathoracic malignancies, such as
on-small cell lung cancer (∼30%).Five-year survival rates for patients with thymic carcinoma are
eported to be 30% in all stages [5];  for patients with advanced-stage
isease, survival time was 20–30 months and 2-year survival rate
ig. 1. (A) The estimated Kaplan–Meier curves for overall survival (n = 40). Median
verall survival from initiation of ﬁrst-line chemotherapy was 24.5 months (95% CI,
0.9-43.5); (B) survival curves for prognostic category comparing responders (n = 19
solid line]) to non-responders (n = 21 [dashed line]). Median survival in the responder
roup was  43.6 months (95% CI, 23.3–not reached), vs. 21.5 months (95% CI, 9.3-33.8)
n  the non-responder group (p = 0.018).ase; MST: median survival time.
was only 50% [5,6,16–19].  In addition, the median survival time
for thymic neuroendocrine carcinoma is 18 months and the 10-
year survival rate is 10–28% [20]. Additionally prognosis is affected
by cellular atypia [7,20].  In the present study, however, no statis-
tically signiﬁcant difference was shown between low-grade and
high-grade histology. Therefore, we  postulate that clinically aggres-
sive or indolent disease could be distinguished even in squamous
histology because survival rates had a wide distribution. The recent
largest study using the Surveillance Epidemiology and End Results
(SEER) cancer database demonstrated that male gender was a factor
for longer survival rates [5].  In our study, however, female gender
showed better prognosis.
The optimal chemotherapy for advanced thymic carcinoma is
still controversial. Conventionally, the Einhorn regimen for germ
cell tumors, which consists of a cisplatin- and anthracycline-
containing triplet or quartet regimen (ADOC [21], and PAC [22]
consisting of cisplatin, adriamycin, and cyclophosphamide), has
been used as ﬁrst-line chemotherapy for thymoma. At present, cis-
platin and adriamycin are considered key drugs for the treatment
of thymoma [23] whereas anthracycline for thymic carcinoma is
controvertial. Thus, cisplatin combination chemotherapy is used
for treating thymic carcinoma. High-dose chemotherapy, such as
VIP [24] (etoposide, ifosfamide, and cisplatin), and CODE [17] (cis-
platin, vincristine, doxorubicin, and etoposide) with granulocyte
colony-stimulating factor, have also demonstrated activity against
advanced thymic carcinoma. Theoretically, dose-intense or dense
chemotherapy should be effective for chemosensitive tumors [25].
However, the response rate to chemotherapy in patients with
thymic carcinoma is approximately half of that seen in patients
with thymoma: the response rate to chemotherapy for thymoma
has been shown to be 60–90% in prospective studies, whereas the
response rate for thymic carcinoma in small retrospective case
studies has been between 25% and 50% [6,16–19]. Among these
Table 3
Multivariate survival analysis among advanced thymic carcinoma patients treated
with chemotherapy.
Variants Hazard ratio 95% CI p-value
Responder (responder vs.
non-responder)
0.37 0.16–0.81 0.01*
Histology (high-grade vs. low-grade) 0.85 0.34–1.90 0.70
Staging (IVa/IVb vs. recurrent) 1.48 0.62–4.11 0.40
CI: conﬁdence interval.
* p < 0.05.
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Table 4
Efﬁcacies and toxicities in previous reported chemotherapy for advanced thymic carcinoma.
Reference Regimen No of
patients
CR + PR
(%)
PFS (mo) MST  (mo) 1-year
survival (%)
2-year
survival (%)
Febrile
neutropenia (%)
Gr 3/4 hematological
toxicities (%)
Anthracycline containing regimens
Agatsuma et al. [16] ADOC/ADOCb 34 50 N/A 21.3 N/A N/A 11.8 76.5
Yoh  et al. [17] CODE 12 42 5.6 46 80 58 33.3 91
Non-anthracycline containing regimens
Lemma  et al. [6] Carboplatin/paclitaxel 21 24 5.0 20.0 N/A N/A 8.7 24.4a
Igawa et al. [18] Carboplatin/paclitaxel 11 36 7.9 22.7 62 N/A 0 82
Okuma et al. [19] Cisplatin/irinotecan 9 55.6 7.9 33.8 77.7 55.6 0 22.2
CR: complete response; PR: partial response; PFS: progression free survival; MST: median survival time; Gr: grade; N/A: not available.
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[a Grade 4 hematological toxicities were reported among all 44 patients of thymo
herapies, platinum-doublet chemotherapy for advanced thymic
arcinoma was recently shown to lead to a moderate response,
ith adequate survival and less toxicity [6,18,19] (Table 4). Addi-
ionally, it is recommended that the efﬁcacy of chemotherapy be
valuated by time-to-event, such as progression-free survival, and
ot by tumor response alone [26]. Thus, an optimal chemotherapy
egimen for advanced thymic carcinoma has not been determined
n spite of its efﬁcacy against for thymoma.
Single-agent chemotherapy such as 5-ﬂuorouracil and leucov-
rin [27], amrubicin [28], S-1 [29], and somatostatin analog plus
rednisolone [30], are candidate for later lines of chemotherapy.
nalyses of molecular-targeted agents are still being performed. In
he future, based on c-kit gene mutant status, molecular-targeted
rugs that inhibit c-KIT, such as imatinib [31], sorafenib [32], and
unitinib [33], may  provide promising effectiveness [34]. In our
eries, although the role of later lines of chemotherapy was still
nclear, the patients who responded to ﬁrst-line chemotherapy
eemed to be sensitive to later lines of chemotherapy (p = 0.31).
owever, the use of later lines of chemotherapy was predominant
n patients with more than 2-year survival. Patients who received
ater lines of chemotherapy were mostly treated with a single-
gent. Thus, chemotherapy-sensitive cases may  be beneﬁcial with
hemotherapy when the patients are able to maintain good perfor-
ance status.
The present study demonstrated that response to ﬁrst-line
hemotherapy was the only factor associated with a signiﬁcantly
etter prognosis. The correlation between tumor response to
hemotherapy and survival has been previously investigated for
everal cancers. The prognostic value of histologic response is
till controversial. In clinical trials, analysis of survival by tumor
esponse is not recommended to evaluate chemotherapy response
ecause tumor response does not always reﬂect the beneﬁt of
hemotherapy against cancers in terms of prolongation of sur-
ival [35]. However, the initial response could act as a prognostic
arker showing which patients might have longer survival. This
tudy showed that response to ﬁrst-line chemotherapy might lead
o longer survival because patients have a better sensitivity to
hemotherapy. Clinical characteristics such as age, sex, staging,
erum LDH level, and histology were not shown to be signiﬁcant
rognostic factors.
One limitation of our study was the small number of patients.
owever, this is a common limitation in studies of thymic car-
inoma because it is a rare cancer. In addition, the effectiveness
f chemotherapy for survival is not evident because comparing a
ontrolled randomized trial with the best supportive care is not
ealistic in the rare cancers. However, as with other rare cancers,
ncontrolled clinical trials have shown prolonged survival numer-
cally, and we cannot help but treat patients with high consensus.
The results of this study suggest that the prognosis for advanced
hymic carcinoma could be predicted based on sensitivity to ﬁrst-
ine chemotherapy. Thus, the response for ﬁrst-line chemotherapy
[d thymic carcinoma.
may  be implicated as a potential surrogate for survival in advanced
thymic carcinoma.
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